| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.59B | 18.44B | 14.91B | 17.43B | 17.23B | 14.63B |
| Gross Profit | 9.66B | 8.98B | 7.05B | 7.78B | 7.87B | 6.81B |
| EBITDA | 7.01B | 6.34B | 4.91B | 5.64B | 5.71B | 4.89B |
| Net Income | 5.81B | 5.36B | 3.83B | 4.51B | 4.61B | 3.91B |
Balance Sheet | ||||||
| Total Assets | 21.90B | 21.35B | 18.74B | 18.78B | 17.20B | 15.89B |
| Cash, Cash Equivalents and Short-Term Investments | 6.69B | 6.39B | 5.85B | 5.37B | 3.66B | 5.73B |
| Total Debt | 4.48B | 4.76B | 4.98B | 5.01B | 5.01B | 5.00B |
| Total Liabilities | 11.71B | 11.48B | 10.21B | 10.57B | 10.92B | 9.86B |
| Stockholders Equity | 10.19B | 9.86B | 8.54B | 8.21B | 6.28B | 6.03B |
Cash Flow | ||||||
| Free Cash Flow | 5.85B | 5.41B | 4.26B | 4.68B | 2.55B | 3.24B |
| Operating Cash Flow | 6.38B | 6.17B | 4.65B | 5.18B | 3.10B | 3.59B |
| Investing Cash Flow | -783.59M | -708.09M | -370.61M | -534.56M | 612.27M | 73.27M |
| Financing Cash Flow | -4.96B | -4.94B | -4.00B | -2.83B | -4.58B | -4.17B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $405.53B | 39.51 | 51.72% | 0.63% | 24.91% | 39.95% | |
77 Outperform | $216.38B | 37.96 | 62.26% | 0.56% | 25.66% | 46.68% | |
77 Outperform | $203.32B | 29.61 | 35.51% | 0.69% | 4.47% | 0.48% | |
77 Outperform | $163.67B | 39.11 | 99.17% | 0.58% | 22.27% | 45.32% | |
69 Neutral | $31.78B | 29.18 | 11.17% | 2.32% | 8.01% | 10.41% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
57 Neutral | $23.28B | 45.39 | 3.00% | 1.28% | -17.33% | -76.71% |
On November 4, 2025, Lam Research Corporation held its annual meeting of stockholders, where key decisions were made, including the approval of a new equity incentive plan, the 2025 Stock Incentive Plan. Additionally, an amendment to the company’s Restated Certificate of Incorporation was approved, limiting the liability of certain officers as permitted by Delaware law. These changes, along with the election of directors and other proposals, reflect Lam Research’s strategic efforts to enhance corporate governance and align executive compensation with shareholder interests.